Boston, MA, United States of America

Zhengyu Ouyang

This inventor holds 1 USPTO granted patent and 1 EPO patent. Top assignees: Massachusetts Institute of Technology, The General Hospital Corporation, University of California. Active years: 2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Zhengyu Ouyang. Retrieved from https://idiyas.com/inventor/zhengyu-ouyang

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

 

Average Co-Inventor Count = 1.0

ph-index = 1


Company Filing History:


Years Active: 2026

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Zhengyu Ouyang: Innovator in Immune Cell Research

Introduction

Zhengyu Ouyang is an accomplished inventor based in Boston, MA (US). He has made significant contributions to the field of immune cell research. Although he currently holds no granted patents, his work is focused on advancing our understanding of immune cell phenotypes.

Latest Patent Applications

Zhengyu Ouyang's latest patent application is titled "Methods for Identifying and Modulating Immune Phenotypes." This invention provides tools and methods for the systematic analysis of genetic interactions in immune cells. It offers innovative approaches for modulating immune cell phenotypes, combinatorial probing of cellular circuits, and delineating molecular pathways. The application aims to identify relevant targets for therapeutic development.

Conclusion

Zhengyu Ouyang is a notable figure in the realm of immune research, with a focus on developing methods that could lead to significant advancements in therapeutic applications. His contributions, although not yet reflected in granted patents, hold promise for future innovations in the field.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…